Abstract
The emerging field of miRNA research has proven to be a promising contributor
to modern medicine in recent times. miRNA has successfully provided the
medical science community a new vision into the understanding of various types
of diseases through clinical trials. Most of the research and clinical trials
on miRNA are related to disease-specific profiling and functional analysis.
Success of these trials would substantiate the role played by miRNAs in
disease pathogenesis and thereby, facilitate the development of suitable
therapeutics.
According to our latest report entitled, "Global miRNA Market Outlook", the
global research on miRNA is expected to grow at a stupendous rate in the
coming years. Both, private and public sectors are stepping forward to provide
huge financial support to fund these promising researches. Major
pharmaceuticals and biotechnology companies are also showing impending
interest in the research and research-related product segments. Such, high
growth in the miRNA research is likely to boost the miRNA analysis of the
products' industry.
Currently, the research community is primarily focusing on the widespread
chronic diseases, such as Cancer, Hepatitis, and Diabetes. Additionally, miRNA
and its role in various diseases are being studied from a genetic point of
view. Success in these areas would eventually fuel the movement into other
important and rare diseases.
Our research also shows that the US and European countries including France,
Germany, and Italy are the leading regions with a flourishing miRNA market.
Asian countries, like India, China, Japan, and Singapore are also moving
progressively into the field and are likely to become considerably large
potential markets.
The report includes various techniques, like miRNA labeling, miRNA
purification, etc., which are being used in the miRNA research. It provides a
detailed description on the role of miRNAs in the pathogenesis of various
diseases that is likely to provide a comprehensive overview of the miRNA
market and its prospects.
Table of Contents
1. Analyst View
2. Research Methodology
3. miRNA - An Introduction
4. Ongoing miRNA Research
- 4.1 Global Research Overview
- 4.1.1 Cancer
- 4.1.2 Cardiovascular Diseases
- 4.1.3 Metabolic Diseases
- 4.1.4 Muscle Disorders
- 4.2 Key Geographical Markets
- 4.2.1 US
- 4.2.2 Europe
- 4.2.3 Asia Pacific
- 4.3 miRNA Techniques
- 4.3.1 miRNA Purification
- 4.3.2 miRNA Labeling
- 4.3.3 miRNA Linear Amplification
- 4.3.4 miRNA Microarrays
- 4.3.5 miRNA qRT-PCR
- 4.3.6 miRNA Inhibition
5. Key Players
- 5.1 Life Technologies Corporation
- 5.2 Mirus Bio LLC
- 5.3 QIAGEN NV
- 5.4 Promega Corporation
- 5.5 Thermo Fisher Scientific, Inc.
- 5.6 Agilent Technologies
- 5.7 Exiqon
- 5.8 System Biosciences
List of Figures:
- Figure 3-1: miRNA Biogenesis
- Figure 4-1: Global - Geographic Distribution of miRNA Researchers (%)
- Figure 4-2: Global - Breakup of Type of Studies Utilizing miRNAs (%)
- Figure 4-3: US - miRNA Market (Million US$), 2008 & 2015
- Figure 4-4: miRNA Expression Profiling - Market Segmentation by Type of
Technology Utilized (%), 2008
List of Tables:
- Table 4-1: miRNAs associated with Cancer
- Table 4-2 Overview of Dysregulated miRNAs with Validated Targets Important
for the Cardiovascular System
- Table 4-3: miRNAs with Altered Expression in Obesity and the Metabolic
Syndrome
- Table 4-4: US - List of Ongoing miRNA Research
- Table 4-5: Europe - List of Ongoing miRNA Research
- Table 4-6: Asia-Pacific - List of Ongoing miRNA Research
- Table 4-7: miRNA Purification Products by Supplier
- Table 4-8: miRNA Labeling Products by Supplier
- Table 4-9: miRNA Linear Amplification Products by Supplier
- Table 4-10: miRNA Microarray Products by Supplier
- Table 4-11: miRNA qRT-PCR Products by Supplier
- Table 4-12: miRNA Inhibition Products by Supplier
Global miRNA Market Outlook published by RNCOS E-Services Pvt. Ltd. in December 1, 2011. This report consists of 60 Pages and the price starts from US $ 1000.
The contents of this page may be different from the latest version. Please contact us for details.
